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ABSTRACT 
Ethnopharmacological relevance: The Natal gwarri or Natal ebony (Euclea natalensis 
A.DC.) is a deciduous tree found widespread throughout southern Africa, especially in 
Kwazulu-Natal and the southern cost. It has been widely used by indigenous communities 
such as the Zulus, Tsongas and Vendas for symptoms related to tuberculosis (TB). The 
decoctions made from the plant parts are administered for chest diseases to treat 
complications such as chest pains, bronchitis, pleurisy and asthma. TB is prevalent in 
immune-compromised patients and it is evident that TB-drugs cause hepatotoxicity. The 
objective of the present study was therefore to evaluate the antimycobacterial activity of the 
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ethanolic extract of E. natalensis against TB and its hepatoprotective and immunomodulatory 
activities. 
Materials and methods: The antimycobacterial, antioxidant, hepatoprotective, 
immunomodulatory activity and cytotoxicity of the ethanolic extract of the shoots of E. 
natalensis were determined in vitro. The mechanism of action of the antituberculosis activity 
was determined by investigating the inhibitory effect on mycothiol disulfide reductase 
enzyme. Furthermore, the acute, sub-acute toxicity (50-2000 mg/kg) and antimycobacterial 
effect (300 mg/kg) of E. natalensis shoot extract were investigated in Balb/c mice. 
Hepatoprotective activity of the extract (50-150 mg/kg) was evaluated on isoniazid and 
rifampicin (50 mg/kg; i.p.) induced hepatic damage in a rat model. 
Results: The minimum inhibitory concentration of the extract was found to be 125 µg/ml 
against Mycobacterium tuberculosis. The extracts fifty percent inhibitory concentration (IC50) 
against 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical was found to be 22.55 µg/ml. The 
plant showed a hepatoprotective effect (50% at 12.5 µg/ml) and the ability to increase T-
helper 1 cell cytokines; Interleukin 12, Interleukin 2 and Interferon α by up to 12 fold and the 
ability to decrease the T-helper 2 cell cytokine Interleukin 10 4 fold when compared to 
baseline cytokine production. No cellular toxicity was observed in primary peripheral blood 
mononuclear cells (PBMC’s) and two secondary cell lines; U937 monocytes and Chang liver 
cells (a derivative of the HepG2 cell line). During mechanistic studies, the extract showed a 
50% inhibition of mycothiol reductase activity at 38.62 µg/ml. During the acute and sub-
acute studies, E. natalensis exhibited no toxic effect and the fifty percent lethal dose (LD50) 
was established to be above 2000 mg/kg. The extract was able to reduce the mycobacterial 
load (1.5-fold reduction) in infected mice. Isoniazid and rifampicin caused significant hepatic 
damage in rats, and the extract was able to reduce the toxicity by 15% and 40% at 50 and 150 
mg/kg respectively. 
Conclusion: The present study supports the traditional usage of the plant against tuberculosis 
symptoms. The study showed the ability of E. natalensis shoot extract to inhibit 
mycobacterial growth, stimulate an appropriate immune response and have a hepatic 
protective effect. Due to the extract’s significant results for hepatoprotective, 
immunomodulatory effects and antimycobacterial activity, it may prove to be effective to 
serve as an adjuvant for TB-patients. 
 
Keywords: Euclea natalensis, Antimycobacterial, Toxicity, Immunomodulation, 
Hepatoprotection. 
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1. Introduction 
Tuberculosis remains one of the world’s deadliest infectious diseases with an annual 
incidence rate of more than 9 million and death rate of 1.3 million in 2014 (WHO, 2016). 
Termed as a disease of poverty, it is the middle and low-income countries that are affected 
the most. 
Although effective, the current treatment regime for tuberculosis (TB) is not without 
complications. The time required to treat TB can range from 6-9 months. This time duration 
not only increases the risk of a patient infecting more individuals but also increases the risk of 
the patient developing drug-induced hepatic damage (Sia and Wieland, 2011). Secondly, 
during tuberculosis infection, an imbalance between the T-helper cell 1 (Th1) and T-helper 
cell 2 (Th2) human immune responses exist, where it has been shown that an increase in the 
Th1 response could potentially be used as an immune therapy for active TB infections (Wong 
et al., 2013). Thirdly, the increase in multidrug- (MDR-TB) and extensive drug (XDR-TB) 
resistance tuberculosis is on the rise and the development of new drugs and treatment is an 
on-going process (Allerberger et al., 2016; Ma et al., 2010). An adjuvant with 
hepatoprotective effect, antioxidant activity, which can stimulate the production of the Th1 
cytokines and which can target the appropriate enzymes and mechanism to combat resistance 
is imperative. When developing a new drug or adjuvant, these aspects should be considered. 
One of the targets, in the causative organism, Mycobacterium tuberculosis, has been 
identified as Mycothiol disulfide reductase (Mtr), which is not targeted by any of the existing 
tuberculosis drug. Mycothiol, the product of Mtr is the low molecular weight thiol, which 
maintains the oxidative stress environment within the bacterium cell. This enzyme is distinct 
from the human analogue, glutathione reductase, making Mtr the ideal enzyme target for drug 
and product development (Hernick, 2013; Mdluli and Spigelman, 2006; Zhang, 2005). 
Throughout history, the human civilization has been depending and relying on natural 
products to treat their ailments. These products were obtained from flora, fauna and mineral 
sources from the indigenous people’s immediate surroundings and more remote areas. Nature 
has been the source of medicinal agents for thousands of years, and a staggering number of 
modern drugs have been isolated from natural sources, especially plants (Ghorbani et al., 
2006). Over the last few decades, there has been a significant increase and a growing interest 
in alternative medicines, especially those from plant origin (Ekor, 2013; WHO, 2004). This 
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green revolution can be attributed to several reasons; conventional medicine can be 
inefficient, abusive and incorrect use of these drugs can result in adverse side effects. A large 
percentage of the world’s population does not have access to conventional pharmacological 
treatment. Lastly, indigenous medicine and ecological awareness suggest that “natural” 
products are safe and harmless (Rates, 2001). However, this is not always the case and the 
use of these natural products are not always authorized by legal authorities or practitioners 
that are familiar with the efficacy and safety of the phytomedicine. There are many articles 
and published papers that report on the lack of quality and safety in the production, trade and 
prescription of phytomedicinal products (Ekor, 2013; Govindaraghavan and Sucher, 2015; 
Pelkonen et al., 2014; Raynor et al., 2011). It is clear that modern society’s general views of 
health services, the need for new novel pharmaceutical drug development and the recognition 
that research in and on ethnopharmacology as an alternative, represents a viable and suitable 
approach for new drug development and research. 
Many plants have been used traditionally to treat the symptoms of tuberculosis. According 
to previous research done, some plants have shown significant activity against 
Mycobacterium in in vitro studies, with a minimum inhibitory concentration (MIC) of lower 
than 50ug/ml. These plants include; Berchemia discolor with an MIC of 12.5 µg/ml, 
Warbugia salutaris (25 µg/ml), Terminalia sericea (25 µg/ml), Bridelia micrantha, and 
Diospyros mespiliformis (12.5 µg/ml) (Green et al., 2010; Mahapatra et al., 2007). Euclea 
natalensis, a plant belonging to the Ebenaceae family has been used by multiple communities 
in southern Africa including, Tsonga, Shangaan, Venda and the Zulu tribes. Mainly and most 
importantly this plant has been used for the treatment of chest complaints. Decoctions from 
parts of E. natalensis have been made to treat chest pains, bronchitis, pleurisy and asthma. It 
has also been used against leprosy (caused by Mycobacterium leprosy). Other uses include; as 
a dye and the shoots are chewed as a tooth cleaning instrument (Bryant, 1909). Chemical 
profiling of Euclea natalensis have produced an array of isolated compounds and the 
antitubercular activity has mostly been associated with the isolated naphthoquinones; 7-
methyl juglone, diospyrin, isodiospyrin, neodiospyrin and shinanolone. These compounds 
have been isolated in higher quantities in the roots of the plant but are also present in lower 
quantities, in the shoots (Bapela et al., 2007). During an earlier study the MIC’s of 7-methyl-
juglone, diospyrin, isodiospyrin, neodiospyrin and shinanolone were found to be 0.5 µg/ml, 
8.0 µg/ml, 10.0 µg/ml, 10.0 µg/ml and 100 µg/ml respectively (van der Kooy et al., 2006).  
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The present study investigated E. natalensis’ ability to indirectly combat this disease by 
means of assessing its antimycobacterial, immunomodulatory as well as hepatoprotective 
activity. By combining antibacterial activity with immunomodulation a double edged sword 
can be produced to directly kill the bacteria and boost the human immune response to 
indirectly help the patient in combating the disease. The cytotoxic effect of the extract was 
investigated against primary peripheral mononuclear cells and secondary Chang liver and 
U937 cell lines in vitro, and acute and sub-acute toxicity in Balb/c mice, in vivo. The 
mechanism of action was evaluated on Mycothiol reductase enzyme. 
2. Materials and methods 
2.1. Collection, authentication, and extraction of plant 
Shoots of Euclea natalensis A. DC. were collected from Edakeni, Kwazulu-Natal, South 
Africa, identified and authenticated at the H.G.W.J. Schweickerdt Herbarium (PRU 95059). 
The dried shoot material (5 kg) was mechanically ground to a fine powder using a 2mm sieve 
and extracted using 95% ethanol in a 1:10 ratio for 4 days. The extract was filtered using a 
Buchner funnel, and concentrated to dryness in a rotary evaporator (Büchi Rotavapor R-200) 
under reduced pressure and controlled temperature (37 – 40°C) and percentage yield was 
found to be 10%. 
2.2. In vitro antimycobacterial activity 
A drug-susceptible strain of M. tuberculosis, H37Rv (ATCC 27264) was obtained from 
American Type (MD) USA Culture Collection. M. tuberculosis was plated onto Löwenstein-
Jensen medium and allowed to grow for 3-4 weeks at 37 °C. A single bacterial colony was 
transferred into fresh 7H9 media supplemented with 10% OADC and 2% PANTA and 
incubated for another 3 weeks. 
A 96-well microtitre plate was used to determine the minimum inhibitory concentrations 
(MIC) of E. natalensis extract according to the method of Franzblau and collaborators 
(1998), with slight modifications. The extract was dissolved in 20% DMSO in sterile 
Middlebrook 7H9 media supplemented with 10% OADC and 2% PANTA to obtain a stock 
solution of 200 mg/ml. The extract was tested in triplicate in four independent assays. A two-
fold serial dilution of the extract was made to yield a final concentration ranging from 1000 
μg/ml to 3.13 μg/ml. Isoniazid (INH), at final concentrations ranging from 4.0 μg/ml to 0.03 
μg/ml, served as the positive drug control. Control wells without the tested plant extracts and 
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a solvent control, DMSO at a final concentration of 5%, were included in the assays. Two 
hundred microliters of sterile distilled water were added to all the perimeter wells of the plate 
to compensate for evaporation. The plates were sealed with Parafilm and incubated at 37ºC 
for 5 days. Forty microliters of freshly prepared 1:1 mixture of Alamar Blue reagent and 10% 
Tween 80 were added to the medium control well, and re-incubated at 37ºC for 24 h. After 
observing a colour change from blue to pink, Alamar blue reagent was added to the rest of the 
test wells and incubated at 37ºC for an additional 24 h. The minimum inhibitory 
concentration (MIC) was defined as the lowest concentration where no colour change from 
blue to pink was observed. 
2.3. In vitro antioxidant activity 
The method of du Toit and collaborators (2001), with slight modification, was followed to 
determine the radical scavenging capacity (RSC) of the extract. Briefly, stock solutions of 
ascorbic acid and the extract were prepared at concentrations of 2 mg/ml and 10mg/ml 
respectively. The assay was performed in a 96-well microtitre plate. The final test 
concentrations ranged from 3.9 µg/ml to 500 µg/ml for the extract and 0.781 µg/ml to 100 
µg/ml for ascorbic acid. Lastly, 0.04 M 2, 2-diphenyl-1-picrylhydrazyl radical (DPPH) 
ethanolic solution was added to each test well, except for the negative control where distilled 
water was used. The plate was kept in the dark for 30 minutes. The scavenging activity was 
determined using a BIO-TEK Power-Wave XS multi-plate reader, measuring DPPH 
concentrations at a wavelength of 515 nm. 
2.4. In vitro cell cytotoxicity 
Cytotoxicity of the extract was evaluated using the method as described by Lall and 
collaborators (2013). The cell lines (primary peripheral blood mononuclear cells, U937 
monocytes and chang liver cells) were seeded (100 µl) in 96-well microtitre plates at a 
concentration of 1×10
5 
cells/ml. The plates were incubated for 24 h at 37ºC and 5% CO2 to 
allow the cells to adhere. The extract was dissolved in DMSO and the final test concentration 
of the extract ranged from 1.563 µg/ml to 400 µg/ml. The microtitre plates were incubated 
for a further 72 h. The control wells included vehicle treated cells exposed to 0.04% DMSO 
and the positive control, ‘Actinomycin D’ with concentrations ranging between 0.002 µg/ml 
to 0.5 µg/ml. After the 72 h incubation period, Prestoblue reagent (20 µl) was added and the 
plates were further incubated for another 2 hours. After the incubation, the absorbance of the 
colour complex was read at 570 nm with a reference wavelength set at 600 nm using a BIO-
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TEK Power-Wave XS multi-well plate reader. The assay was performed in triplicate to 
calculate a fifty percent inhibitory concentration (IC50) of the cell population. 
2.5. In vitro immunomodulation assay 
Peripheral blood mononuclear cells (PBMC’s) were isolated and assessed for their 
cytokine production after the treatment with shoot extract. The selection criteria of 
volunteers/patients were based on healthy volunteers above the age of 21 with no history of 
any major diseases. The study was approved by the ethics committee of the Faculty of 
Natural and Agricultural Sciences (EC120411-046, University of Pretoria, South Africa). The 
PBMC’s were isolated using a density gradient centrifugation utilizing Ficoll-Hypaque 
(Sigma, St. Louis, MO), described previously by Traoré and Meyer (2007). Briefly, the buffy 
coat was carefully collected and the cells were treated for 5 minutes with cell lysis buffer to 
remove the contamination of erithrocytes. The cells were cultured in peridishes for 1 hour at 
37°C to allow the attachment of monocytes. Non adherent cells were removed by washing 
twice with PBS. The cells were cultured at a concentration of 1x10
5
 cells/ml in 24-well plates 
in RPMI 1640 medium containing 10% inactivated foetal bovine serum. To differentiate the 
monocytes into macrophages, 2 g/ml of PHA (Phytohaemagglutinin, Sigma-Aldrich) was 
added for 24 h at 37°C in a 5% CO2 incubator. Differentiated cells were treated with the 
extract prepared at half the IC50 concentrations as determined by the cytotoxicity assay. As 
controls, untreated cells, cells treated with solvent (0.5% DMSO) and cells treated with the 
positive control (Septilin at 5 µg/ml) were used. A viability test was conducted, after 
incubation, to determine the viability of the cells when supernatants were collected. The test 
plates were incubated for 18-24 hours at 37ºC with 5%CO2. After incubation, the plates were 
sealed and centrifuged for 5 min at 800g. Supernatants were collected in 150 µl aliquots and 
used directly or stored at -72ºC.  
The cell-free supernatant obtained from treated peripheral blood mononuclear cells were 
analysed for their immune stimulatory effects by assessing the cytokine production. Two 
methods were utilised; Sandwich enzyme-linked-immunosorbent-assay (ELISA) (OptEIA™ 
Human IL12 (p40) ELISA, BD Biosciences) for the analysis of Interleukin 12 cytokine and 
Cytometric bead array (Cytometric Bead Array (CBA) Human Th1/Th2, BD Biosciences) 
flow-cytometry for the other Th1/Th2 cytokines. The kits were used according to the 
manufacture's instruction. 
2.6. In vitro hepatoprotective assay 
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Human HepG2 cells were adjusted to be 1 x 10
5
 cells/ml in Eagle's minimal essential 
medium (EMEM) supplemented with 10% FBS, and 100 μl of the cell suspension were 
plated into 96-well culture plate and incubated at 37ºC in a humidified 5% CO2 incubator for 
16 h overnight. Post incubation, the cells were treated separately with varying concentrations 
of extract ranging between 3.1-100 µg/ml and incubated for 24 h. Silymarin (6.25 to 25 
μg/ml) was used as a positive control. After incubation, the cells were treated with 30 mM of 
D-galactosamine and incubated for 24 h. Thereafter, the supernatant was discarded and the 
cells were washed with PBS, the fresh growth medium along with 3-(4,5-Dimethylthiazol-2-
yl)-2,5-Diphenyltetrazolium Bromide (MTT) was added and incubated for 1 h to allow the 
formation of formazan crystals. Finally, the medium was removed, and the formazan crystals 
were dissolved using DMSO; the absorbance was measured at a wavelength of 570 nm. 
2.7. In vivo acute and subacute toxicity 
The animals used in the toxicity studies were approved by the Animal Use and Care 
Committee (AUCC T005-12). The acute and sub-acute toxicity studies were carried out on 
female Balb/c mice (8 weeks old) by administering the extract orally. For the acute toxicity 
study the mice received two single doses at different instances, according to the Organisation 
for Economic Co-operation and Development (OECD) guidelines for preclinical toxicity 
testing, at 300 and 2000 mg/kg. For the sub-acute toxicity study, a two-week study was 
conducted with a single dose daily at 0, 100, 200 and 300 mg/kg of the extract, according to 
the OECD guidelines. 
2.8. In vivo antimycobacterial activity 
The extract was tested for its antimycobacterial activity in Mycobacterium tuberculosis 
H37Rv infected mice. The animals used for the infection study was approved by the 
institutional University of Pretoria Animal Ethics Committee (EC027-13). Briefly, Balb/c 
mice, infected by utilizing aerosol infection at 10
6
 cfu/ml, were randomly divided into four 
groups of five animals per group. The vehicle control group (5% DMSO), a positive control 
group was administered with once a day dosing of pyrazinamide and rifampicin (75 mg/kg 
and 1000 mg/kg per mouse, respectively). The test group received 300mg/kg per mouse of 
plant extract together with the positive drugs and the last group received only the plant 
extract at 300 mg/kg, daily. Twenty-four hours after infection 5 untreated mice were 
sacrificed to determine baseline infection in lungs by means of bacterial cultivation. Four 
weeks after TB infection another 5 untreated mice were sacrificed prior to the 
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commencement of treatment to determine the bacterial loads in lungs at the beginning of 
treatment. Dosing commenced 4 weeks after infection and continued for 4 weeks. The 
animals were monitored daily. 
2.9. In vivo hepatoprotective effect 
The hepatoprotective activity of E. natalensis in vivo was assessed using a rat model of 
Isoniazid- and rifampicin-induced hepatotoxicity according to the method of Ilyas and 
collaborators (2011) with slight modifications. The animals used in the hepatoprotective 
study were approved by the Animal Use and Care Committee (AUCC, T006-13). After 7 
days of acclimation, the Sprague-Dawley rats were randomly divided into five groups 
consisting of six rats per group. The first group served as an untreated control group. The 
negative control group received only intoxicant (Isoniazid and rifampicin at 25 mg/kg 
intraperitoneally). Positive drug control group received Silymarin at 50 mg/kg with the 
intoxicant. The experimental drug groups received E. natalensis extract at doses of 50 and 
150 mg/kg together with the intoxicant. The experimental drugs were administered orally to 
the groups of rats, once per day for 30 days. Twenty-four hours after the last administration, 
all rats in each group were anaesthetized with isoflurane and then sacrificed. Blood was 
collected and liver tissues were immediately removed and frozen away at -80°C until further 
analysis. 
2.10. Mode of action of the extract 
The experimental procedure as described by Hamilton and collaborators (2009) with slight 
modifications was used to determine the enzyme inhibition potential of the E. natalensis 
extract, on mycothiol (Mtr) reductase. Briefly, the inhibition assay with Mtr was carried out 
at 30ºC in a 96-well microplate, assay volume of 200 µl, with 50 mM Hepes (pH 7.6), 0.1 
mM EDTA, 70 µM NADPH, 100 µM Ellman’s reagent (DTNB, 5,5′-dithiobis-(2-
nitrobenzoic acid)), and substrate (60 µM). The extract was dissolved in DMSO, and the final 
concentrations ranged from 7.8 – 500 µg/ml. Mtr was pre-incubated with NADPH for 5 min 
at 30ºC before initiating the reaction by the addition of the substrate. Enzyme activity was 
monitored by means of the increase in absorbance at 405 nm due to the formation of TNB 
(5′-mercapto-2-nitrobenzoic acid) via the continuous DTNB-coupled assay. The kinetic read 
intervals were set to capture data every 15 seconds and the assay was left to run for 15min at 
a set temperature of 30°C. Initial rates were measured from the linear region of the progress 
curve. The IC50 was calculated from a 4-parameter sigmoidal regression line. 
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2.11. Homology modelling 
Mycobacterium tuberculosis mycothiol reductase (Mtr) sequence was retrieved from 
UniProtKB/TrEMBL database (primary accession number A0A0T9X864) (Boeckmann et al., 
2003). To identify homologous sequences with known 3D structure, a BLASTP (protein-
protein Basic Local Alignment Search Tool) search was carried out against the protein data 
bank (PDB) (Altschul et al., 1990; Bernstein et al., 1977). It searches a database of available 
protein structures with sequences to identify homologous structure using a query protein 
sequence with no structure. A number of sequences homologous to Mtr were obtained. The 
top hit 1GER (E. coli – Glutathione reductase) showed good alignment with 30% sequence 
identity (abundance of exact amino acid at particular position in query and target sequences) 
and an E-value (expectation value: signifies error that may occur by chance) of 5e-48 with 
Mtr sequence. Generally, a lower E-value indicates that alignment is real. MODELLER9.16 
was used for comparative protein modelling (Šali et al., 1995). Simultaneous modelling of the 
ligand in the Mtr protein was carried out using template 1BWC (human glutathione reductase 
(Gtr) complexed with ajoene inhibitor), as it can be assumed that the ligand binding modes 
are similar to the target and the template proteins. Accordingly, ligands were then transferred 
among target structures, keeping their orientation as a restraint for the subsequent modelling 
process. Subsequently, models were selected on the basis of high molpdf score and subjected 
to loop refinement and model validation using iterative evaluation of Ramachandran plot, 
ERRAT plot and ProSA Z-core (Colovos and Yeates, 1993; Lovell et al., 2003; Wiederstein 
and Sippl, 2007).  
2.12. Molecular docking 
Compounds previously isolated and reported from Euclea natalensis were selected for 
molecular docking on mycothiol reductase. These include; 7-methyl juglone (MIC on TB – 
0.5 µg/ml), menadione (100 µg/ml), shinanolone (100 µg/ml), diospyrin (8 µg/ml) and 
neodiospyrin (10 µg/ml) (Bapela et al., 2007; van der Kooy et al., 2006). These compounds 
have also been isolated and identified in the shoots and also in the shoot extract used in this 
study (Bapela et al., 2007; Tannock, 1973; van der Vijver and Gerritsma, 1974). The 
compounds were selected based on their antimycobacterial activity (Mahapatra et al., 2007; 
van der Kooy et al., 2006). Molecular docking was performed using GOLD (Genetic 
Optimization for Ligand Docking) program (Jones et al., 1997). It uses genetic algorithm 
considering ligand flexibility and partial protein flexibility (Verdonk et al., 2003). The default 
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docking parameters were employed for docking study. It performs 100,000 genetic operations 
on a population size of 100 individuals and mutation rate 95. The homology model of Mtr 
was used for docking study. The structures of compounds were sketched using Chemdraw3D 
and minimized considering rmsd cut-off of 0.10Å. The docking protocol was set by 
extracting and re-docking the ajoene inhibitor in the Mtr homology model with rmsd ~1.0Å. 
It was followed by docking of compounds isolated from E. natalensis in the active site 
defined as 5Å regions around the ajoene inhibitor in Mtr protein. Further, all molecules were 
evaluated for possible molecular interactions with Mtr active site residues using PyMol 
molecular visualizer (DeLano, 2002). 
2.13. Statistical analysis 
All data were analysed using GraphPad Prism 4. Sigmoidal dose-response curves were 
analysed using a 4-parameter nonlinear regression. Tukey’s multiple comparison tests were 
performed by one-way analysis of variance (ANOVA). A P-value lower than 0.05 was 
considered to be statistically significant. All data are expressed as Mean ± SD. 
3. Results and discussion 
3.1. In vitro antimycobacterial, antioxidant, cytotoxic, immunomodulation and 
hepatoprotective activity 
The pharmacodynamics of the extract was evaluated and is summarized in Table 1. The 
minimum inhibitory concentration (MIC) of the Euclea natalensis ethanolic shoot extract on 
a drug-sensitive strain of Mycobacterium tuberculosis (H37Rv) was found to be 125 µg/ml. 
The positive control Isoniazid (INH) exhibited an MIC of 0.25 µg/ml. Our results were 
comparable to some of the studies conducted earlier. In a study conducted by Nguta et al., 
(2016), five selected medicinal plants were assessed for their antimycobacterial activities, one 
plant extract of Solanum torvum exhibited an MIC below 200 µg/ml, whereas the other 
extracts’ MIC’s ranged between 2500 and 10 000 µg/ml on the tested Mycobacterium spp. 
During hepatic damage caused by long exposure of TB-drugs, antioxidants play a vital role in 
protecting and decreasing hepatic injury. The DPPH scavenging activity of the extract was 
evaluated and the extract and ascorbic acid exhibited an IC50 of 22.55 ± 2.93 µg/ml and 4.34 
± 0.48 µg/ml, respectively. During the study conducted on the cytotoxic effect of E. 
natalensis on peripheral blood mononuclear cells, U937 monocytes and Chang liver cells, the 
plant extract showed low cellular toxicity on primary PBMC’s (IC50 131.3 ± 1.67 µg/ml), 
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secondary U937 monocytes (IC50 208.9 ± 10.3 µg/ml) and Chang liver cells (IC50 148.2 ± 8.3 
µg/ml). An IC50 below 50 µg/ml has been considered to be moderately toxic and samples 
with a toxicity value higher than 100 µg/ml have been considered to be non-toxic 
(Vijayarathna and Sasidharan, 2012). In the study mentioned above, the cytotoxicity of the 
ethanolic extract of Solanum torvum was assessed on human fetal lung fibroblasts (MRC-5) 
and the IC50 of the extract was found to be 31.25 µg/ml (Nguta et al., 2016). The cytokine 
levels produced by the treated PBMC’s were analysed and evaluated. The baseline 
production of cytokines by the isolated PBMC’s was of low values, and the addition of the 
sample had a significant effect on the cytokine production. From Table 2 it is evident that 
there was an increase in all four Th1 cytokines when compared to the baseline and three out 
of the four Th1 cytokines when comparing to a known immune stimulant. Interleukin 2 
showed the greatest increase from baseline to treatment, followed by TNFα and Interleukin 
12. Interleukin 2 is involved in the activation of T lymphocytes together with Interferon, and 
these have been shown to limit the replication of mycobacteria (Johnson et al. 2003). 
Macrophage cell-proliferation, regulated by IL2, has been shown to be decreased in patients 
suffering from TB (Toossi et al. 1986). The ability of the extract to induce the production of 
these cytokines can possibly greatly aid the immune response in combating and inhibiting the 
proliferation of the bacteria. There was also a decrease in one of the Th2 cytokines and no 
effect on the other. This indicates a selectivity of the extract towards Th1 response. This 
suggests strongly the immunomodulatory properties of the extract.  
E. natalensis extract was evaluated for its possible hepatoprotective activity against D-
galactosamine. Drug-induced liver injury (DILI) remains a problem related to TB drug 
therapy, especially in TB/HIV co-infection, with damage occurring as early as 3 months after 
the start of the treatment (Jong et al., 2013). A significant decrease in cell viability was 
observed upon treatment of HepG2 cells with D-galactosamine (30 mM). Euclea natalensis 
exhibited a significant protection (50±5.9% protection) at a concentration of 12.5 µg/ml 
towards cell toxicity of D-Galactosamine. The reference standard, silymarin demonstrated a 
significant increase in cell viability against D-galactosamine-induced toxicity with a 
protection of 58±6% obtained at 12.5 µg/ml. The mechanism of action on mycothiol 
reductase showed a high inhibition with an IC50 of 38.62 µg/ml (Fig 1)  
13 
 
Table 1  
Effect of Euclea natalensis extract on Mycobacterium tuberculosis inhibition, DPPH scavenging, 
cytotoxicity, and hepatic protection against drug-induced toxicity in human HepG2 hepatocytes. 
Sample & 
reference 
standard 
Antibacteria
l 
Antioxidan
t 
Cytotoxicity 
Hepatoprotectiv
e 
MIC
a
 
(µg/ml) 
IC50
b 
(µg/ml) ± 
SD 
IC50
b 
(µg/ml) ± SD % Protection 
(12.5µg/ml) ± 
SD 
PBMC
c
 
U937
d
 
Chang 
Liver 
E. 
natalensis 
shoot 
extract 
125 22.6 ± 2.9 131.3 ± 
1.7 
208.9 
± 10.3 
148.2 
± 8.3 
50 ± 5.9 
Isoniazid
e
 
0.25 - - - - - 
Ascorbic 
acid
f
 
- 4.34 ± 0.5 - - - - 
Actinom
ycin D
g
 
- - 1.3x10
-
3
 
1.3x10
-2
 
8.2x10
-3 
- 
Sylimari
n
h
 
- - - - - 58 ± 6.0 
a 
Minimum inhibitory activity, 
b
 half maximal inhibitory concentration, 
c
 Peripheral blood 
mononuclear cells, 
d
 human macrophages, 
e
 antimycobacterial standard, 
f 
Antioxidant standard, 
g 
Cytotoxicity standard, 
h 
Hepatoprotective standard, data are represented as Mean ± SD, n=3, ANOVA 
p-value < 0.05 
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Fig. 1. Effect of Euclea natalensis on the inhibition of mycothiol reductase enzyme. Data are 
expressed as Log Mean, n=3, 4-parameter nonlinear regression. 
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Table 2 
Effect of Euclea natalensis on cytokine production and excretion by treated isolated peripheral blood 
mononuclear cells (Th1: IL12, IL2, TNF and IFN. Th2: IL4 and IL10). 
 
Sample 
Cell baseline 
production 
E.natalensis 
5 µg/ml 
Septilin  
5 µg/ml 
Fold increase or 
decrease from baseline 
T
h
1
a 
(p
g
/m
l)
 Interleukin 12 17.27 75.68  59.35  4.38 x increase 
Interleukin 2 0.0 25.88  7.39  >200 x increase 
TNFα c 5.13 66.5  96.95  12.96 x increase 
Interferon 11.76 27.18  9.1  2.31 x increase 
T
h
2
b
 
Interleukin 4 0.0 0.0 0.0 - 
Interleukin 10 8.96 2.34  7.18  3.8 x decrease 
a
T-helper 1 cytokines, 
b
T-helper 2 cytokines, 
cTumor necrosis factor α 
3.2. Mycothiol reductase structure prediction using Homology modelling 
Mtr plays an important role in oxidative stress management and is oxidised to the 
symmetrical disulfide in the process. Mtr monomer has an amino acid sequence length of 
459. To identify homologous sequences of Mtr that could be used as a template for model 
building, a BLASTP search against PDB using Mtr as query sequence was performed. The 
top hit from BLASTP, viz. E. coli - Glutathione reductase (PDB code: 1GER) has a crystal 
structure resolution of 1.86Å, and exhibits 30% sequence identity (Fig. 2). Another, human 
Gtr structure (PDB code – 1BWC) was taken for ligand modelling in the Mtr homology 
model. It has a crystal structure resolution of 2.1Å and showed 29% identity with Mtr 
sequence. This strategy was applied to identify the active site residues around the 6Å region 
of bound inhibitor in 1BWC. Subsequently, mapping these residues in the multiple sequence 
alignment led to hot spot identification in Mtr protein. The final model was validated using 
various tools: 
(1) Ramachandran plot emphasized that Φ (phi) and Ψ (psi) dihedral angle distribution of all 
the amino acids residues in various regions i.e. 89.9% in the core region, 8.3% in allowed 
region and 1.8% in the disallowed region, as presented in Table 3 and Fig S 1respectively. 
This indicated that the backbone dihedral angles in the Mtr model were reasonably accurate. 
(2) An ERRAT plot showed non-bonded interactions between different atom types of amino 
acid. It is helpful to determine the ‘structure error’ at each residue in the 3D structure of the 
protein. It provides an indication for loop refinement at those regions where the plot bar 
exceeds the 95% error value in ERRAT plot, shown in Fig S 2. Loop refinement was 
performed in several cycles, taking a few amino acids in each step and validating through 
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ERRAT plot. ERRAT plot of the loop refined model showed an increase in the overall score 
for structural quality to 96% (Table 3). 
(3) ProSA-web reveals that the ProSA Z-score value is −5.83. It indicated that predicted 
model is in the range of native conformations of the crystal structures, as shown in Table 3 
and Fig S 3. 
(4) RMSD validation criteria include the superimposition of the overall structure and active 
site regions surrounding ajoene inhibitor in both Mtr model and Human Gtr (PDB: 1BWC). 
An RMSD of Cα-backbone for the overall structure was calculated to be 2.5Å (Table 1). 
Further, superimposition of the active site residues within the 5.0Å region surrounding ajoene 
inhibitor (ball and stick) in Mtr (green) and Human Gtr (cyan) showed that ~50% of the 
active site residues were conserved, except that Gly12, Asn15, Leu18, Leu40, Gly95 and 
Asn317 of Mtr were replaced with Ser30, Ala34, Arg37, Val59, Tyr114, and Ile343 in 
Human Gtr respectively (Fig. 2). See appendix A for the supplementary Figures (Fig S1-S3) 
 
Fig. 2. Multiple sequence alignment for building Mtr homology model. 
Table 3 
Validation statistics for developed Mtr homology model 
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Model validation statistics 1GER (Template) Mtr (Model) 
% Amino acids in favoured regions 97.10 89.9 
% Amino acids in allowed regions 2.9 8.3 
% Amino acids in disallowed regions 0 1.8 
Errat overall quality factor 97.47 96.00 
ProSA Z-score -10.99 -5.83 
RMSD with template  2.5Å 
 
3.3. Molecular docking analysis 
Molecular docking was carried out to predict the binding mode of the extract constituting 
compounds in the Mtr active site. A fitness score is a Gold score which is used to rank the 
various docked poses of small molecules. It is derived using the geometrical properties and 
bonding affinities of ligand. All compounds were docked in the active site of Mtr 
successfully. The ajoene inhibitor is present as a co-crystal ligand in 1BWC structure. 
Despite none H-bond interactions at the Mtr active site residues, it showed highest fitness 
score of 44.69 as compared to rest of the compounds. Probably, it may be due to the good 
complementary fitting of this compound into the Mtr active site which makes balanced van 
der Waals interactions with surrounding residues and FAD (flavin adenine dinucleotide) (Fig. 
3). 
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Fig. 3. Interaction of the docked compounds in the Mtr active site. FAD is shown as a green stick and 
ball model. 
It is followed by the 7-methyl juglone which showed a fitting score of 41.10. It showed 
three H-bond interactions with FAD and one H-bond interaction with residue Asn317. It 
makes very close interaction with FAD as shown in Fig 2. Similar to 7-methyl juglone, 
menadione and shinanolone also formed close interactions with FAD and showed fitting 
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scores of 40.26 and 34.22 respectively. Also, the menadione showed one H-bond interaction 
with backbone atom of Gly12 while shinanolone showed two H-bond interactions with 
Gly12. The diospyrin and neodiospyrin showed lowest fitting scores of 26.20 and 24.51 in 
the Mtr active site cavity respectively. This may be due to the bulkiness of these compounds 
which make them dock little away from the region where other make generous fit. It is also 
evident from the Fig.2 where these compounds showed different binding orientation in the 
Mtr active site. Thus, molecular docking study indicated the importance of small molecular 
structures which are supposed to make proper interactions into the Mtr active site cavity.   
3.4. In vivo acute and sub-acute toxicity 
The initial acute toxicity study indicated that a single dose (2000 mg/kg), administered 
orally, did not produce any mortality, toxicity signs or behavioural changes when compared 
to the control group. The dosages were initiated with a single dose of 300 mg/kg and 
increased to 2000 mg/kg when no toxicity was observed. As per acute toxicity results, doses 
of 250, 150 and 50 mg/kg were used in the 2-week long sub-acute study. No unscheduled 
death, clinical or histopathological signs of toxicity were observed. Body weight and organ 
weight showed no sign of toxicity related to dose response. It was established that the LD50 is 
above 2000 mg/kg. 
3.5. In vivo antimycobacterial 
The antimycobacterial activity of E. natalensis shoot extract was evaluated on 
Mycobacterium Tuberculosis (H37Rv) infected Balb/c mice (8-week old). There was a 
substantial decrease in bacterial loads when comparing the infected control group to the 
treatment groups, showing a decrease in lung homogenate colony forming units from 1.5x10
6
 
(Control) to 7.1x10
3
 (Drug control) (Fig. 4.) The extract showed a significant decrease in 
mycobacterial loads when used on its own and in combination with Pyr/RIF (Pyrazinamide, 
75 mg/kg; Rifampicin 1000 mg/kg), reducing the load to 4.8x10
3
 cfu/ml in the lung 
homogenate. No toxicity was observed which could be associated with E. natalensis 
administered together with isoniazid and rifampicin. 
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Fig. 4. Antimycobacterial effect of E. natalensis extract on the reduction of Mycobacterium 
tuberculosis load in infected Balb/c mice Rifampicin (75 mg/kg; p.o.) and Pyrazinamide (1000 mg/kg; 
p.o.) was used as the drug control. Data are expressed as Log Mean±SD, n=5; ** p< 0.01, when 
compared to the control group; *** p< 0.001, when compared to the control and En group; ++ p< 
0.001 when compared to the control, p< 0.005 when compared with the drug control. 
3.6. In vivo hepatoprotective activity 
One liver enzyme Alanine transaminase (ALT) showed significant changes regarding its 
concentration among different groups of animals when ANOVA statistics was used. Serum 
levels of ALT were analysed after 14 days of treatment Isoniazid and rifampicin (comb. 
50mg/kg; i.p.) significantly increased the serum levels, indicating an induced toxicity as 
shown in Fig. 5. Silymarin (positive control; 50 mg/ml; p.o.) was able to reduce the levels by 
almost half. E. natalensis shoot extract showed a positive dose-response in decreasing the 
levels of serum ALT. At a dosage of 50 mg/kg, it was capable of decreasing the levels by 
15% and at 100mg/ml by almost 40%. There exists a link between antioxidant activity and 
hepatoprotective activity. Due to the effective ability of the extract to scavenge free radicals, 
this can contribute to the protection effect and the ultimate reduction of ALT and other toxic 
liver markers. 
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Fig. 5. The hepatoprotective effect of E. natalensis extract on the reduction of ALT levels in INH/Rif 
toxicity induced Sprague-Dawley rats. Isoniazid (25 mg/kg; i.p.) and Rifampicin (25 mg/kg; i.p.) were 
used as the toxic inducer, Silymarin (50 mg/kg; p.o.) was administered as the positive control. Data 
are expressed as Mean±SD, n=6; ANOVA; ** p< 0.05, when compared to the toxic (INH/Rif) group; 
*** p< 0.001, when compared to the toxic (INH/Rif) and En 100 mg/kg group. 
4. Conclusion 
It is conceivable that Euclea natalensis plant extract has shown remarkable biological 
activity, not only antibacterial activity but also an immune stimulatory effect as well as the 
protective effect on liver against toxic inducers. The molecular docking study showed that the 
biological activity is contributed by various compounds present in the extract. However, on 
the basis of fitting score, 7-methyl juglone is predicted to contribute more towards biological 
activity as compared to menadione and shinanolone. E. natalensis shows to be a promising 
adjuvant for patients suffering from Tuberculosis or related symptoms, and the extract should 
be further tested in clinical studies. 
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